Madeline Digges
Pharmacovigilance in hospice/palliative care: Net effect of haloperidol for nausea or vomiting
Digges, Madeline; Hussein, Akram; Wilcock, Andrew; Crawford, Gregory B.; Boland, Jason W.; Agar, Meera R.; Sinnarajah, Aynharan; Currow, David C.; Johnson, Miriam J.
Authors
Akram Hussein
Andrew Wilcock
Gregory B. Crawford
Professor Jason Boland J.Boland@hull.ac.uk
Professor and Honorary Consultant in Palliative Medicine
Meera R. Agar
Aynharan Sinnarajah
David C. Currow
Professor Miriam Johnson Miriam.Johnson@hull.ac.uk
Professor
Abstract
Background Haloperidol is widely prescribed as an anti-emetic in patients receiving palliative care, but there is limited evidence to support and refine its use. Objective To explore the immediate and short-term net clinical effects of haloperidol when treating nausea and/or vomiting in palliative care patients Design A prospective, multi-centre, consecutive case series. Setting/Subjects Twenty-two sites, five countries: consultative, ambulatory and inpatient services. Measurements When haloperidol was started in routine care as an anti-emetic, data were collected at three time points: baseline; 48h (benefits); day 7 (harms). Clinical effects were assessed using the National Cancer Institute’s Common Toxicity Criteria for Adverse Events (NCI CTCAE). Results Data were collected (May 2014 to March 2016) from 150 patients: 61% male; 86% with cancer; mean age 72 (SD 11) years and median Australian-modified Karnofsky Performance Scale 50 (range 10–90). At baseline, nausea was moderate (88; 62%) or severe (11; 8%); 145 patients reported vomiting, with a baseline NCI CTCAE vomiting score of 1.0. The median (range) dose of haloperidol was 1.5mg/24h (0.5–5mg/24h) given orally or parenterally. Five patients (3%) died before further data collection. At 48h, 114 patients (79%) had complete resolution of their nausea and vomiting, with greater benefit seen in the resolution of nausea than vomiting. At day 7, 37 (26%) patients had a total of 62 mild / moderate harms including: constipation 25 (40%); dry mouth 13 (21%); and somnolence 12 (19%). Conclusions Haloperidol as an anti-emetic provided rapid net clinical benefit with low-grade, short-term harms.
Citation
Digges, M., Hussein, A., Wilcock, A., Crawford, G. B., Boland, J. W., Agar, M. R., Sinnarajah, A., Currow, D. C., & Johnson, M. J. (2018). Pharmacovigilance in hospice/palliative care: Net effect of haloperidol for nausea or vomiting. Journal of palliative medicine, 21(1), 37-43. https://doi.org/10.1089/jpm.2017.0159
Journal Article Type | Article |
---|---|
Acceptance Date | Jun 20, 2017 |
Online Publication Date | Aug 3, 2017 |
Publication Date | 2018-01 |
Deposit Date | Jun 28, 2017 |
Publicly Available Date | Aug 6, 2018 |
Journal | Journal of palliative medicine |
Print ISSN | 1096-6218 |
Publisher | Mary Ann Liebert |
Peer Reviewed | Peer Reviewed |
Volume | 21 |
Issue | 1 |
Pages | 37-43 |
DOI | https://doi.org/10.1089/jpm.2017.0159 |
Keywords | Anesthesiology and Pain Medicine; General Nursing; General Medicine |
Public URL | https://hull-repository.worktribe.com/output/452981 |
Publisher URL | http://online.liebertpub.com/doi/abs/10.1089/jpm.2017.0159 |
Additional Information | This is a description of an article which has been published in: Journal of palliative medicine, 2017 |
Contract Date | Jun 28, 2017 |
Files
Article
(162 Kb)
PDF
Copyright Statement
©2018 The Authors.
You might also like
Health service utilisation associated with chronic breathlessness: random population sample
(2021)
Journal Article
Downloadable Citations
About Repository@Hull
Administrator e-mail: repository@hull.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search